Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors

Authors:

Yusra F. Shao, Yasmine Baca, Joanne Xiu, Ari VanderWalde, Gino Kim In, Dave S. B. Hoon, Evidio Domingo-Musibay, Sourat Darabi, Burton Larry Eisenberg, Takami Sato, Geoffrey Thomas Gibney, Hirva Mamdani, Justin C Moser

Key Finding:

Biomarkers of immune checkpoint inhibitor response, like PD-L1 and tumor mutational burden, have low prevalence in uveal melanoma and are not associated with benefit from immune blockade. 

Download Publication